# C.K. Cheng

> C.K. Cheng is a Series D investor at Acorn Pacific Ventures backing Medical and Life Science. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Acorn Pacific Ventures](https://shizune.co/investors/profile/acornpacific-ventures)
- Location: San Francisco Bay Area, United States
- Total investments: 1
- Last investment: Jan 2018
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chih-kai-cheng-8b81bbbb/

C.K. Cheng is a Series D investor at Acorn Pacific Ventures in San Francisco Bay Area focused on Medical and Life Science. Chih-Kai Cheng is the Co-founder and General Partner at Acorn Pacific Ventures. Chih-Kai Cheng attended National Chiao Tung University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Life Science | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Medical Device | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Eureka Therapeutics | Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. The company's platform is a novel T-cell therapy construct that mimics the natural biology of T-cells to fight cancer. It utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancerantigens.Eureka Therapeutics was founded in 2006 and is headquartered in Emeryville, California. | $60M | Series D | Jan 22, 2018 |  |

1 of 1 investments shown.

## Co-investors
- [GP Capital](https://shizune.co/investors/profile/gp-capital) — VC Fund, 1 deal together

## About Acorn Pacific Ventures

VC Fund · Santa Clara, United States

Acorn Pacific Ventures helps entrepreneurs execute technology strategies.

5 contacts available at Acorn Pacific Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| C.K. Cheng | Co-founder and General Partner | https://shizune.co/investors/profile/c-k-cheng-346c |
| Derek Chau | Partner | https://shizune.co/investors/profile/derek-chau |
| Peter Hsieh | General Partner | https://shizune.co/investors/profile/chung-kao-hsieh |
| C.K. Cheng | Co-founder and General Partner | https://shizune.co/investors/profile/c-k-cheng |
| Howard Chau | Partner | https://shizune.co/investors/profile/howard-chau-35f1 |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does C.K. Cheng invest in?

C.K. Cheng invests primarily in Medical, Life Science and Therapeutics startups, most often at Series D stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did C.K. Cheng last invest?

The most recent investment recorded for C.K. Cheng closed in Jan 2018. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co